ASH 2021 | GAIA/CLL13: Venetoclax-based time-limited combination therapies in CLL
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, gives an overview of the Phase III GAIA trial (NCT02950051), which assessed standard chemoimmunotherapy versus a combination of rituximab, venetoclax, obinutuzumab, and ibrutinib in patients with chronic lymphocytic leukemia (CLL). Patients received either standard chemoimmunotherapy, rituximab with venetoclax, obinutuzumab with venetoclax, or obinutuzumab with ibrutinib and venetoclax. Rituximab or obinutuzumab with venetoclax were associated with higher rates of undetectable minimal residual disease (uMRD), and whilst addition of ibrutinib added further benefit to patients, more adverse events were reported. Further research is required to identify patient subgroups who will benefit from chemoimmunotherapy the most. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
